Development of the novel PEG-PE-based polymer for the reversible attachment of specific ligands to liposomes: synthesis and in vitro characterization.
暂无分享,去创建一个
[1] Vladimir P Torchilin,et al. Passive and active drug targeting: drug delivery to tumors as an example. , 2010, Handbook of experimental pharmacology.
[2] V. Torchilin,et al. Targeted accumulation of polyethylene glycol‐coated immunoliposomes in infarcted rabbit myocardium , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[3] G Gregoriadis,et al. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. , 1991, Biochimica et biophysica acta.
[4] J. Cohen,et al. Sterically stabilized liposomes: physical and biological properties. , 1994, Journal of drug targeting.
[5] V. Torchilin,et al. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. , 1991, Biochimica et biophysica acta.
[6] H. Enoch,et al. Formation and properties of 1000-A-diameter, single-bilayer phospholipid vesicles. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[7] V. Torchilin,et al. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. , 2006, Bioconjugate chemistry.
[8] V. Torchilin. Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.
[9] H. Gold,et al. Acute myocardial infarct imaging with indium-111-labeled monoclonal antimyosin Fab. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] G. Ellman,et al. Tissue sulfhydryl groups. , 1959, Archives of biochemistry and biophysics.
[11] Vladimir P Torchilin,et al. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. , 2005, Advanced drug delivery reviews.
[12] H. Gold,et al. Monoclonal antibody to cardiac myosin: imaging of experimental myocardial infarction. , 1984, Hybridoma.
[13] T. Allen,et al. Ligand-targeted liposomes for cancer treatment. , 2005, Current drug delivery.
[14] S. Zalipsky. Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. , 1993, Bioconjugate chemistry.
[15] V. Torchilin,et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. , 2001, Biochimica et biophysica acta.
[16] Samuel Zalipsky,et al. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. , 2004, Advanced drug delivery reviews.
[17] V. Torchilin,et al. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. , 1996, Biochimica et biophysica acta.
[18] V. Torchilin,et al. “Smart” Drug Carriers: PEGylated TATp-Modified pH-Sensitive Liposomes , 2007, Journal of liposome research.
[19] Robert Langer,et al. Lectin-bearing Polymerized Liposomes as Potential Oral Vaccine Carriers , 1996, Pharmaceutical Research.
[20] Willis,et al. Ligand-targeted liposomes. , 1998, Advanced drug delivery reviews.
[21] A A Bogdanov,et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. , 1994, Biochimica et biophysica acta.
[22] M. Woodle,et al. Sterically stabilized liposomes. , 1992, Biochimica et biophysica acta.
[23] F. Muggia. Clinical Efficacy and Prospects for Use of Pegylated Liposomal Doxorubicin in the Treatment of Ovarian and Breast Cancers , 2012, Drugs.
[24] V. Torchilin,et al. Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies. , 1998, Cancer detection and prevention.
[25] A. Habeeb,et al. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. , 1966, Analytical biochemistry.
[26] A. Zimmer,et al. Drug delivery of oligonucleotides by peptides. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[27] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[28] V. Torchilin,et al. Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. , 1995, Immunology letters.
[29] G. Hortobagyi,et al. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] S. Zalipsky. Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. , 1995, Bioconjugate chemistry.
[31] Qiang Zhang,et al. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. , 2005, Journal of pharmaceutical sciences.
[32] T. N. Palmer,et al. The mechanism of liposome accumulation in infarction. , 1984, Biochimica et biophysica acta.
[33] Vladimir P Torchilin,et al. Multifunctional nanocarriers. , 2006, Advanced drug delivery reviews.